Mcf Advisors LLC Biogen Inc. Transaction History

Mcf Advisors LLC

$1.42 Billion
Q3 2024

A detailed history of Mcf Advisors LLC transactions in Biogen Inc. stock. As of the latest transaction made, Mcf Advisors LLC holds 330 shares of BIIB stock, worth $49,176. This represents 0.0% of its overall portfolio holdings.

Number of Shares

330

Previous 330 -0.0%

Holding current value

$49,176

Previous $76,000 17.11%

% of portfolio

0.0%

Previous 0.01%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	BUY	$190.52 - $236.72 $1,143 - $1,420	6 Added 1.85%	330 $76,000
Q1 2024 Apr 16, 2024	SELL	$212.02 - $267.71 $3,180 - $4,015	-15 Reduced 4.42%	324 $69,000
Q4 2023 Feb 01, 2024	SELL	$222.59 - $267.94 $222 - $267	-1 Reduced 0.29%	339 $87,000
Q3 2023 Oct 19, 2023	SELL	$253.3 - $285.89 $9,372 - $10,577	-37 Reduced 9.81%	340 $87,000
Q1 2023 Apr 18, 2023	BUY	$256.56 - $292.34 $30,787 - $35,080	120 Added 46.69%	377 $104,000
Q4 2022 Jan 31, 2023	BUY	$252.44 - $306.72 $1,009 - $1,226	4 Added 1.58%	257 $71,000
Q2 2022 Aug 11, 2022	SELL	$187.54 - $223.02 $1,125 - $1,338	-6 Reduced 2.32%	253 $52,000
Q1 2022 May 05, 2022	BUY	$193.77 - $244.14 $50,186 - $63,232	259 New	259 $54,000
Q4 2021 Feb 14, 2022	SELL	$223.92 - $287.77 $47,023 - $60,431	-210 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$282.99 - $369.05 $1,697 - $2,214	6 Added 2.94%	210 $59,000
Q2 2021 Aug 10, 2021	BUY	$259.0 - $414.71 $4,921 - $7,879	19 Added 10.27%	204 $71,000
Q4 2018 Jan 25, 2019	SELL	$278.5 - $352.75 $5,570 - $7,055	-20 Reduced 9.76%	185 $56,000
Q2 2018 Jul 20, 2018	SELL	$257.52 - $306.91 $772 - $920	-3 Reduced 1.44%	205 $59,000
Q3 2017 Oct 30, 2017	BUY	$281.15 - $329.69 $58,479 - $68,575	208	208 $65,000

Others Institutions Holding BIIB

# of Institutions

1,037

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.5B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mcf Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mcf Advisors LLC with notifications on news.

Account